Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm
- 1 September 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Proceedings of the American Thoracic Society
- Vol. 3 (7) , 594-600
Abstract
Pulmonary endarterectomy (PEA) is recommended as the treatment of choice for eligible patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, only a proportion of patients fulfill the criteria for surgical intervention. In addition, operated patients with CTEPH may experience a gradual hemodynamic and symptomatic decline related to a secondary hypertensive arteriopathy in the small precapillary pulmonary vessels. It has also been questioned what can be done to reduce risks from PEA surgery to improve outcome in “high risk” patients with CTEPH with substantial impairment of pulmonary hemodynamics before surgery. Such patients may benefit from preoperative reduction of pulmonary vascular resistance by means of medical therapy. Conventional medical treatments, such as anticoagulation, diuretics, digitalis, and chronic oxygen therapy, show low efficacy in the treatment of CTEPH as they do not affect underlying disease processes. Over the last decade, several novel therapies have been developed for pulmonary arterial hypertension (PAH), including prostacyclin analogs (epoprostenol, beraprost, iloprost), endothelin receptor antagonists (bosentan, sitaxsentan, ambrisentan), and phosphodiesterase-5 inhibitors (sildenafil). Evidence of efficacy in PAH, coupled with studies showing histopathologic similarities between CTEPH and PAH, provides a rationale to extend the use of some of these medications to the treatment of CTEPH. However, direct evidence from clinical trials in CTEPH is limited to date. This article reviews evidence supporting, and issues surrounding, the possible use of novel PAH medications in CTEPH.Keywords
This publication has 48 references indexed in Scilit:
- Does rapid dose titration affect the hepatic safety profile of Bosentan?Vascular Pharmacology, 2006
- Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunctionVascular Pharmacology, 2005
- Chronic thromboembolic pulmonary hypertensionCardiology Clinics, 2004
- Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertensionJACC, 2004
- Pulmonary endarterectomy: experience and lessons learned in 1,500 casesThe Annals of Thoracic Surgery, 2003
- Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomyThe Annals of Thoracic Surgery, 2003
- Prostanoids for Pulmonary Arterial HypertensionAmerican Journal of Respiratory Medicine, 2003
- Role of Angiotensin II, Endothelin-1, and Nitric Oxide in HgCl2-Induced Acute Renal FailureToxicology and Applied Pharmacology, 1998
- Predictors of mortality in pulmonary thromboendarterectomyThe Annals of Thoracic Surgery, 1996
- Ca/CaM-Stimulated and cGMP-Specific Phosphodiesterases in Vascular and Non-Vascular Tissues1991